MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

MiNK Therapeutics, Inc. (NASDAQ:INKT) has received an average rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $37.50.

Several research analysts have recently issued reports on INKT shares. HC Wainwright raised MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Friday, August 15th. Zacks Research upgraded shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. Wall Street Zen cut shares of MiNK Therapeutics to a “strong sell” rating in a research note on Saturday, August 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. Finally, B. Riley upgraded shares of MiNK Therapeutics to a “strong-buy” rating in a report on Friday, July 18th.

MiNK Therapeutics Trading Up 4.1%

Shares of NASDAQ:INKT opened at $13.77 on Thursday. The firm’s 50 day moving average is $14.39 and its two-hundred day moving average is $12.72. The firm has a market capitalization of $62.24 million, a P/E ratio of -4.78 and a beta of 0.33. MiNK Therapeutics has a 52 week low of $4.56 and a 52 week high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51). Analysts predict that MiNK Therapeutics will post -2.75 EPS for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.